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to the outcome in CCBT, and both credibility and expectancy
tend towards signiﬁcance in the TAU group. Credibility and
expectancy do not contribute to the outcomes of the combined
treatment. CONCLUSIONS: Patients’ initial belief about the
success of their depression treatment can inﬂuence the outcome.
Taking the patient’s pre-treatment expectancy and credibility
into account may contribute to a more effective treatment.
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OBJECTIVES: To measure the persistence over time of
intended and unintended effects on community based depres-
sion treatment in the U.S. associated with the FDA warnings on
antidepressants and suicidality. In October 2003 the U.S. FDA
issued a Public Health Advisory about the risk of suicidality for
pediatric patients on SSRI antidepressants; a boxed warning
and medication guide were implemented in February 2005, and
later extended to young adults aged 19–24. Unintended
declines in diagnosis and non-SSRI substitute treatment have
been shown immediately following the advisory both for pedi-
atric patients, and for adult patients not targeted by the warn-
ings. Whether those changes persisted is unknown.
METHODS: Pediatric, young adult, and adult cohorts with
newly diagnosed episodes of depression were created using a
national, integrated managed care claims (commercially avail-
able from PHARMetrics®, a Unit of IMS, Inc.) from July
1999-June 2006 (n = 55,218 youth; 44,141 young adults;
394,524 adults patients with new episodes). Time series analy-
ses compared post-FDA advisory trends to expected trends
based on pre-advisory patterns. RESULTS: Young adult and
adult populations mirrored changes in pediatric depression care
after the FDA advisory. Reductions in national rates of depres-
sion treatment were substantial, returning national diagnosing
rates to 1999 levels for pediatric patients and to 2003 levels for
adults. Primary care providers continued signiﬁcant reductions
in new diagnoses of depression (50% lower for pediatric, 40%
lower for young adult, 30% lower for adult). Substitute care by
psychiatrists or psychologists, psychotherapy, and anxiolytic
and atypical antipsychotic medication use did not signiﬁcantly
change from pre-advisory trends. CONCLUSIONS: Declines in
depression diagnosis continued after the advisory. Substitute
care did not compensate. Spillover to adults continued. Results
suggest that the unintended effects were substantial, diffuse,
and non-transitory in a large national population. Policy
actions are required to counter the unintended consequences of
reduced depression treatment.
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OBJECTIVES: A pilot survey was conducted to determine which
NHS services and resources may possibly be impacted in the
management of adverse events (ADEs) related to antipsychotic
use. METHODS: Ten UK mental health specialists were inter-
viewed. The six-question survey advised participants to assume
that patients’ psychotic symptoms were controlled or that it was
too early in therapy to determine efﬁcacy. The ADEs considered
were limited to those identiﬁed by NICE as most troublesome,
i.e. sedation, extrapyramidal symptoms (EPS), weight gain and
sexual dysfunction. RESULTS: The most common routine tests
performed were: full blood count, glucose, cholesterol and
weight. Action was prompted for sedation and sexual dysfunc-
tion only if the patient raised a concern. For weight gain and EPS,
clinician and patient concerns were given equal consideration.
Actions taken in order of preference were: sedation—decrease
dose, change timing, switch treatment; EPS—decrease dose, add
anticholinergic, switch treatment; weight gain—switch treat-
ment, decrease dose; sexual dysfunction—decrease dose, switch
treatment, add sildenaﬁl. Referrals were mentioned in all
responses but were most commonly associated with weight gain
and sexual dysfunction. Most common tests requested as a result
of an ADE assessment were: glucose, weight, cholesterol and
prolactin. Switching treatment was the most common action in
response to positive tests results for any ADE. CONCLUSIONS:
This pilot survey highlights that ADEs could play a substantial
role in treatment costs given the potential use of resources linked
to their observation, diagnosis and management. As such, in
order to comprehensively calculate the cost-effectiveness of any
antipsychotic treatment, acquisition costs as well as costs asso-
ciated with potential adverse event management should be con-
sidered. To conﬁrm the ﬁndings of this survey, further in-depth
research is warranted.
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OBJECTIVES: To fully describe patients’ characteristics, man-
agement patterns, predictive recurrence factors and economic
impact of health care attention of bipolar patients population in
Spain. The description of the sample of an ongoing cohort study
is being presented. METHODS: Prospective observational
cohort study with a follow-up of 12 months including consecu-
tive outpatients diagnosed of Bipolar Disorder I or II (DSM-IV-
TR), stabilized for at least 2 months, who had at least a mood
disorder episode (depression, mania, hypomania or mixed) in the
last year. RESULTS: A total of 571 patients were included,
60.1% women. Mean age was 47.4 years (SD 13.1). Only 37.5%
were active workers, up to 5.4% were having temporal disability
leave and 16.2% were permanent disabled for working. Regard-
ing study disease, 75% were bipolar I and mean time since
diagnosis was 12.3 years (SD 10.5), although time since ﬁrst
mood episode compatible with bipolar diagnose was 16.3 years
(SD 11.2). Mean mood episode number since disease onset was
10.6 (SD 9.3). Up to 74.1% of patients had been hospitalised
during the disease evolution, mean times were 3.6 (SD 3.3).
21.3% of patients have had a suicide attempt. Regarding the
baseline evaluation, 29.9% of patients were not free of mood
symptoms even being stabilized for at least two months, present-
ing more than two mania symptoms (10.6%) and more than 2
depression symptoms (18.2%). CONCLUSIONS: Even in the
stabilization phase of the disease there is an important symptoms
load. Although depressive symptoms are more frequent than
manic symptoms, both subsyndromal symptoms are present in
euthimic bipolar patients. Bipolar disorder is a relevant chronic
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